Back to News
Market Impact: 0.28
Intelligent Bio Solutions Seeks FDA Clearance For Fingerprint-Based Drug Screening System
Source: Nasdaq
Healthcare & BiotechRegulation & LegislationProduct Launches
Intelligent Bio Solutions submitted a 510(k) premarket notification to the FDA seeking clearance for its Intelligent Fingerprinting Drug Screening System to detect the opiate codeine. The filing could expand the system's testing capabilities if cleared, but the outcome and timing of FDA review remain uncertain.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.25
Ticker Sentiment
INBS0.45
More News
- Xencor reports phase 1 data for cancer drug XmAb819
- Biotech stocks are surging. How investors can play the new drug innovation boom
- UK immigration crackdown threatens £15 billion care sector
- Ukraine says Starlink and Starshield high speed restrictions have been lifted
- IMDELLTRA® IN COMBINATION WITH IMFINZI® REDUCED RISK OF DEATH BY AN UNPRECEDENTED 58% IN FIRST-LINE EXTENSIVE STAGE SMALL CELL LUNG CANCER
- How This County Made the Data Center Boom Pay Off
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- AI Financial Research Benchmarks: What the Scores Mean
- State of M&A and Private Markets, June 2026: A $4.9 Trillion Rebound, Underwritten on Money That Never Got Cheaper